View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
The FDA has approved the first and only slow-setting fibrin sealant to be used as a tissue adhesive for adhering autologous skin grafts to surgically prepared wound beds. The product is indicated to treat burns in adult and pediatric patients.
Fibrin sealants contain the proteins fibrinogen and thrombin, which are important to blood clotting. Called Artiss, the new sealant contains a lower concentration of thrombin than similar products. This buys the surgeon more time to position the graft before it adheres to the patient's tissue (about 60 seconds, compared with 5 to 10 seconds with rapid-setting fibrin sealants). Artiss also contains a synthetic protein called aprotinin that delays the breakdown of blood clots. A clinical trial showed that Artiss is as safe and effective as surgical staples for attaching skin grafts on wound sites.
Adverse reactions in patients treated with Artiss included bleeding and fluid collection in the tissues, which are common problems with all skin grafts. For more information, visit the manufacturer's Web site at http://www.baxter.com.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top